| 1. |
|
|
| 2. |
- Tandstad, T., et al.
(författare)
-
One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group
- 2014
-
Ingår i: Annals of Oncology. - : Elsevier BV. - 0923-7534 .- 1569-8041. ; 25:11, s. 2167-2172
-
Tidskriftsartikel (refereegranskat)abstract
- The SWENOTECA group treated 517 clinical stage I nonseminoma patients with one course of adjuvant BEP in a prospective study. The median follow-up is 7.9 years. One course of adjuvant BEP reduced the risk of relapse by over 90%. The relapse rates were 1.6% in low-risk disease and 3.2% in high-risk disease. One course of adjuvant BEP should be considered a standard adjuvant treatment option.SWENOTECA has since 1998 offered patients with clinical stage I (CS I) nonseminoma, adjuvant chemotherapy with one course of bleomycin, etoposide and cisplatin (BEP). The aim has been to reduce the risk of relapse, sparing patients the need of toxic salvage treatment. Initial results on 312 patients treated with one course of adjuvant BEP, with a median follow-up of 4.5 years, have been previously published. We now report mature and expanded results. In a prospective, binational, population-based risk-adapted treatment protocol, 517 Norwegian and Swedish patients with CS I nonseminoma received one course of adjuvant BEP. Patients with lymphovascular invasion (LVI) in the primary testicular tumor were recommended one course of adjuvant BEP. Patients without LVI could choose between surveillance and one course of adjuvant BEP. Data for patients receiving one course of BEP are presented in this study. At a median follow-up of 7.9 years, 12 relapses have occurred, all with IGCCC good prognosis. The latest relapse occurred 3.3 years after adjuvant treatment. The relapse rate at 5 years was 3.2% for patients with LVI and 1.6% for patients without LVI. Five-year cause-specific survival was 100%. The updated and expanded results confirm a low relapse rate following one course of adjuvant BEP in CS I nonseminoma. One course of adjuvant BEP should be considered a standard treatment in CS I nonseminoma with LVI. For patients with CS I nonseminoma without LVI, one course of adjuvant BEP is also a treatment option.
|
|
| 3. |
- Bushlya, V., et al.
(författare)
-
Sintering of binderless cubic boron nitride and its modification by β-Si3N4 additive for hard machining applications
- 2020
-
Ingår i: International Journal of Refractory Metals and Hard Materials. - : Elsevier BV. - 0263-4368. ; 86
-
Tidskriftsartikel (refereegranskat)abstract
- This study present the results of HP-HT sintering, microstructure, properties, and performance of binderless cBN tool material. Within the investigated sintering temperature range of 1900–2600 °C the optimum was found to be 2200–2300 °C. Lower temperature results in incomplete diffusion bonding between cBN grains, while higher temperature results in high degree of recrystallization of initial structure, grain growth, and even formation of hexagonal boron nitride in triple joints. Introduction of stress-inducing β-Si3N4 minor inclusions resulted in high overall mechanical and thermal properties: HK = 41 GPa; KIC = 12.6 MPa·m1/2; λ = 180 W/(m·K). Machining experiments in roughing of hardened tool steels show that binderless cBN material provides high performance in terms of resistance to tool cratering, chipping, and tool fracture.
|
|
| 4. |
|
|
| 5. |
- Kryzhanivskyy, V, et al.
(författare)
-
An inverse problem for retrieving time dependency of heat flux in metal cutting via linear programming
- 2018
-
Ingår i: Procedia Manufacturing. - : Elsevier BV. - 2351-9789. ; 25, s. 287-293
-
Tidskriftsartikel (refereegranskat)abstract
- The paper addresses the inverse heat transfer problem, in which the dependence of the flux on time is determined on the basis of the measured temperatures in remote points of the tool body. The nonlinear heat equation is considered since the properties of the tool material are temperature-dependent. The machining time interval is divided into subintervals within which the change in the tool material properties is ignored. Therefore, it possible to consider a sequence of linear programming problems, each of which minimizes the maximum deviation of the measured temperatures from the calculated ones.
|
|
| 6. |
|
|
| 7. |
- Puuvuori, E., et al.
(författare)
-
PET-CT imaging of CD69 in rheumatoid arthritis model
- 2022
-
Ingår i: European Journal of Nuclear Medicine and Molecular Imaging. - : SPRINGER. - 1619-7070 .- 1619-7089. ; 49:SUPPL 1, s. S279-S280
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
|
|
| 8. |
|
|
| 9. |
- Tandstad, T., et al.
(författare)
-
Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA)
- 2016
-
Ingår i: Annals of Oncology. - : Elsevier BV. - 0923-7534 .- 1569-8041. ; 27:7, s. 1299-1304
-
Tidskriftsartikel (refereegranskat)abstract
- A total of 1118 patients with clinical stage I seminoma one course of adjuvant carboplatin or managed by surveillance were included. Stromal invasion of rete testis and tumor size > 4 cm are confirmed as risk factors predicting relapse. Relapse rates following one course of adjuvant carboplatin is high and there is need to explore more effective adjuvant treatment options in patients with seminoma.The purpose of the protocol was to reduce the treatment burden in clinical stage I (CSI) seminoma by offering risk-adapted treatment. The protocol aimed to prospectively validate the proposed risk factors for relapse, stromal invasion of the rete testis and tumor diameter > 4 cm, and to evaluate the efficacy of one course of adjuvant carboplatin. From 2007 to 2010, 897 patients were included in a prospective, population-based, risk-adapted treatment protocol implementing one course of adjuvant carboplatin AUC7 (>n = 469) or surveillance (>n = 422). In addition, results from 221 patients receiving carboplatin between 2004 and 2007 are reported. At a median follow-up of 5.6 years, 69 relapses have occurred. Stromal invasion of the rete testis [hazard ratio (HR) 1.9, >P = 0.011] and tumor diameter > 4 cm (HR 2.7, >P < 0.001) were identified as risk factors predicting relapse. In patients without risk factors, the relapse rate (RR) was 4.0% for patients managed by surveillance and 2.2% in patients receiving adjuvant carboplatin. In patients with one or two risk factors, the RR was 15.5% in patients managed by surveillance and 9.3% in patients receiving adjuvant carboplatin. We found no increased RR in patients receiving carboplatin < 7 x AUC compared with that in patients receiving a parts per thousand yen7 x AUC. Stromal invasion in the rete testis and tumor diameter > 4 cm are risk factors for relapse in CSI seminoma. Patients without risk factors have a low RR and adjuvant therapy is not justified in these patients. The efficacy of adjuvant carboplatin is relatively low and there is need to explore more effective adjuvant treatment options in patients with high-risk seminoma. The data do not support the concept of a steep dose response for adjuvant carboplatin.
|
|
| 10. |
|
|
